CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

RadNet beats Q3 adjusted EPS estimates, lifts 2026 outlook

By Reuters News


Overview

  • U.S. imaging services provider's Q3 revenue rose 22% yr/yr

  • Adjusted EPS for Q3 beat analyst expectations

  • Company raised full-year 2026 revenue, adjusted EBITDA, and free cash flow guidance


Outlook

  • RadNet raises 2026 Imaging Center revenue guidance to $2.385-$2.435 bln

  • Company now expects 2026 Imaging Center Adjusted EBITDA of $350-$363 mln

  • RadNet increases 2026 Imaging Center Free Cash Flow guidance to $120-$130 mln


Result Drivers

  • VOLUME AND SERVICE MIX - Co cited higher advanced imaging volumes, new center openings, increased capacity utilization, and a greater share of advanced imaging procedures as key drivers

  • ADVANCED IMAGING GROWTH - Advanced imaging volumes and business mix increased, contributing to overall revenue growth

  • REIMBURSEMENT AND DIGITAL HEALTH - Improved commercial payor reimbursement and Digital Health segment revenue growth supported results


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Adjusted EPS

Beat

$0.30

$0.21 (8 Analysts)

Q3 EPS

$0.05

Q3 Net Income

$19.15 mln

Q3 Income from operations

$30.26 mln

Q3 Operating Expenses

$608 mln

Q3 Pretax Profit

$27.51 mln

Q3 Total Service Revenue

$638.26 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • Wall Street's median 12-month price target for RadNet, Inc. is $95.50, about 25.7% above its November 6 closing price of $76.00

  • The stock recently traded at 97 times the next 12-month earnings vs. a P/E of 90 three months ago


Reuters Recommended Reads

  • Nov 5 - Natera Q3 revenue beats estimates; raises 2026 outlook

  • Nov 5 - Biodesix Q3 revenue misses estimates on seasonality impact, project delays

  • Nov 5 - Fulgent Genetics Q3 revenue rises 8% on improved collection rates


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.